Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to ...

Shares of Abbott Laboratories advanced 3.74% to $131.35 Thursday, on what proved to be an all-around poor trading session for ...

In a report released on March 27, Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), with a ...

We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks ...

We recently published a list of the 10 Best S&P 500 Stocks to Buy for Dividend Growth. In this article, we are going to take ...

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s ...

Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.

Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.